Skip to main content
SMFM 2026 Pregnancy Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared outside of the session
Faculty have requested this content not be shared outside of the session
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Recording available 2/16-5/2
Recording available 2/16-5/2
AIUM Credit
AIUM Credit
Foundation Awardee
Foundation Awardee
Poster Icons
Abstract Award
Abstract Award
Foundation Awardee
Foundation Awardee

Poster Session 1

Category: Hypertension

Poster Session 1

(255) Assessing Aspirin Recommendation for Pre-eclampsia

Wednesday, February 11, 2026
10:30 AM - 12:00 PM  
Objective:
USPSTF provides guidance on clinical risk factors warranting daily low-dose aspirin (ASA) to prevent preeclampsia (PreE). However, adherence to these recommendations remains challenging. We aimed to assess provider ASA recommendations among patients with PreE, stratified by USPSTF-defined risk level and self-reported race.

Study Design:
This retrospective study examined patients diagnosed with PreE delivering at a regional academic center between Jan 2022-Mar 2023. Data were extracted from electronic records. Patients were stratified by race and by USPSTF definitions of low, moderate, or high risk. Prenatal and delivery records were reviewed by one investigator for presence of patient risk factors and documentation of provider ASA recommendation. Low risk patients were excluded because black race is a moderate risk factor. A 4-level categorical variable was created: no ASA, moderate risk; yes ASA, moderate risk; no ASA, high risk; and yes ASA, high risk.  Chi-square tests were used to evaluate differences by race and other risk factors.

Results:
Among 5,527 patients who delivered, 440 (7.96%) patients had PreE, with 363 (6.57%) of those in the moderate or high-risk groups.  Among the 363, 56.5% (n=205) were moderate risk and 43.5% (n=158) were high risk. Black patients were less likely to have a documented ASA recommendation compared to non-black patients, in both moderate (12.8% vs 19%) and high-risk groups (25.5% vs 37.7%) (p=0.021) (Fig 1). Other than self-reported race, the only risk factor associated with ASA recommendation was pregestational diabetes, which was significantly associated with a higher likelihood of documented ASA recommendation (p=0.049, data not shown).

Conclusion:
Gaps remain in ASA prophylaxis, with notable racial disparities. Interventions to improve risk identification, documentation, and equity are needed. The association between p</span>regestational diabetes and ASA may reflect earlier access to MFM care. Given persistent inequities and underutilization, universal ASA prophylaxis may be a population-level strategy to improve maternal outcomes.